Patents by Inventor Elisabetta Bianchi
Elisabetta Bianchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12007120Abstract: An oven assembly includes a cooking chamber having a rear wall, a pair of opposed side walls, a top wall, a bottom wall, and an access opening defined by an outer perimeter of the cooking chamber. A movable door operably is coupled with the oven assembly for selectively enclosing the cooking chamber about the outer edge of the cooking chamber. A removable bottom trim panel is disposed proximate a bottom edge of the outer perimeter and includes a tray body. A removable fastening mechanism is disposed on the tray body or the bottom edge and operably couples the tray body to the bottom edge, such that the removable fastening mechanism is adapted to removably attach the removable bottom trim panel to the bottom edge.Type: GrantFiled: December 20, 2021Date of Patent: June 11, 2024Assignee: WHIRLPOOL CORPORATIONInventors: Fabio Bianchi, Elisabetta Bressan
-
Publication number: 20240173309Abstract: The present invention relates to novel lipidated peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof, corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of autoimmune inflammation diseases and/or related disorders.Type: ApplicationFiled: October 26, 2023Publication date: May 30, 2024Inventors: Santhosh NEELAMKAVIL, Chengzao SUN, Sandeep SOMANI, Stephanie A. BARROS, Raymond J. PATCH, Jing ZHANG, Douglas RIEXINGER, Charles HENDRICK, Elisabetta BIANCHI, Roberto COSTANTE, Federica ROSOLIA, Martina LOLLOBRIGIDA, Sonia DEL RIZZO, Danila BRANCA, Ashok BHANDARI, James DANIEL, Tran Trung TRAN, Brian FREDERICK
-
Publication number: 20240150405Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.Type: ApplicationFiled: October 23, 2023Publication date: May 9, 2024Inventors: Chengzao SUN, Brian Troy FREDERICK, Sandeep SOMANI, Gregory Thomas BOURNE, Raymond PATCH, Ashok BHANDARI, Raffaele INGENITO, Roberto COSTANTE, Danila BRANCA, Elisabetta BIANCHI
-
Patent number: 11969403Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.Type: GrantFiled: September 1, 2020Date of Patent: April 30, 2024Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati, Clara Bianchi
-
Patent number: 11932705Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: August 29, 2022Date of Patent: March 19, 2024Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20230406885Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, A1, A2, R1-R7, R8a, R8b, R9a, R9b, R10 and R11 are as herein described. can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: June 13, 2023Publication date: December 21, 2023Applicant: MERCK SHARP & DOHME LLCInventors: Faben A. Cruz, Danqing Feng, Zhuyan Guo, Jennifer Hanisak, Jennifer L. Hickey, Charles Lee Jayne, Ahmet Kekec, Michael Man-Chu Lo, Christopher W. Plummer, Elisabetta Bianchi, Stefania Colarusso, Emanuela Nizi, Francesca Pavone, Ali Munaim Yousif
-
Patent number: 11773150Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: GrantFiled: August 27, 2020Date of Patent: October 3, 2023Assignees: Merck Sharp & Dohme LLC, Ambrx, Inc.Inventors: Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
-
Publication number: 20230303625Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: September 27, 2022Publication date: September 28, 2023Applicant: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20230285514Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: ApplicationFiled: December 18, 2020Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
-
Publication number: 20230270825Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: ApplicationFiled: December 18, 2020Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
-
Patent number: 11725036Abstract: A biologically active single chain Relaxin peptide having the formula Nter-Ac-L-E-G-R-E-K-V-R-A-X19-I-X21-X22-E-G-X25-S-T-F-S-X30-R-A-X33-NH2-Cter, or a salt of solvate thereof, is described.Type: GrantFiled: October 30, 2020Date of Patent: August 15, 2023Assignee: SanofiInventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Publication number: 20230159592Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.Type: ApplicationFiled: June 30, 2022Publication date: May 25, 2023Inventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole HA, Jian Liu, Sobhana Babu Boga
-
Publication number: 20230122330Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: August 29, 2022Publication date: April 20, 2023Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20230105982Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.Type: ApplicationFiled: July 28, 2021Publication date: April 6, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
-
Publication number: 20230063794Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: ApplicationFiled: December 18, 2020Publication date: March 2, 2023Applicant: Merck Sharp & Dohme LLCInventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
-
Patent number: 11566057Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.Type: GrantFiled: September 21, 2018Date of Patent: January 31, 2023Assignee: Merck Sharp & Dohme LLCInventors: Anandan Palani, Qiaolin Deng, Chunhui Huang, Yuping Zhu, Elisabetta Bianchi, Federica Orvieto
-
Publication number: 20220402983Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.Type: ApplicationFiled: January 14, 2021Publication date: December 22, 2022Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Ashok Bhandari, Raymond Patch, Stephanie Barros, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
-
Patent number: 11530244Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11505575Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 22, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11492385Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.Type: GrantFiled: August 26, 2020Date of Patent: November 8, 2022Assignee: Merck Sharp & Dohme LLCInventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto